Business Wire

Mavenir Proves AMD Technology across its Open RAN OpenBeam™ Radio and Converged Packet Core Portfolio

Share

Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud, today announced new initiatives in collaboration with AMD to help Communication Service Providers (CSPs) in their transition to cloud-native telecommunication networks.

First, Mavenir and AMD have been collaborating in Open RAN to build industry leading radio technology. Mavenir has incorporated the AMD Zynq™ Ultrascale+™ RFSoC devices into Mavenir’s OpenBeam™ Radio Portfolio and, through this partnership, both companies continue to work together to introduce new functionality, features, and capabilities to customers.

Secondly, Mavenir’s Converged Packet Core has been validated on AMD EPYC™ CPUs – This means Mavenir’s cloud-native, fully containerized, virtualized Converged Packet Core (4G & 5G) solution can now be deployed on AMD EPYC server CPUs to provide CSPs with more options to implement virtual network functions in cloud data centers.

The elements validated include AMF, SMF, UPF, UDSF, NRF, NSSF, AUSF, UDM, and UDR network functions. Additionally, PCF, NEF, BSF, MME, SecGw, PCRF, MME and SGSN network functions will be validated in the coming months.

“Mavenir’s commitment to enabling networks built on software that runs on any cloud revolves around giving CSPs the ability to use the best components that fit their specific needs, in the cell-site and in the data center,” said Bejoy Pankajakshan, EVP, Chief Technology and Strategy Officer, Mavenir. “Mavenir and AMD are working together to give CSPs multiple options and help them optimize power consumption, network efficiency and total cost of ownership in the radio access as well as the core network.”

“Cloud-native telecom networks empower CSPs with systems that offer flexibility, lower operational cost, ease of system management, and a broader ecosystem for value add, innovation, and upgrade capabilities as network requirements grow,” said Salil Raje, senior vice president and general manager, Data Center and Communications Group, AMD. “We are extremely proud of our close collaboration with Mavenir to help deliver exceptional TCO and predictable scalability along with high performance and power efficient solutions to telecommunications operators leveraging AMD data center products.”

Mavenir’s OpenBeam innovative radio portfolio is specifically designed for the growing needs of CSPs with agile, cost-efficient, intelligent radios to meet critical demands on the network now, and as the network changes and expands. The radio solutions can be used for a wide range of use cases, including basic coverage across all frequency bands, outdoor small cells, for public and private networks providing business and consumer services in both urban and rural environments.

Mavenir’s Converged Packet Core is an end-to-end, fully containerized portfolio that offers multi-generational support to modernize existing mobile networks while providing a cost-effective journey to 5G. Its cloud-native architecture, with applications and services purpose-built for the cloud model, offers easy scaling, hardware decoupling, agility, portability and resiliency across public, private and hybrid clouds. Its web-scale granular microservice architecture meets carrier-grade requirements such as high availability, security, and performance.

To know more about the joint collaboration, visit Mavenir (hall 2 stand 2H60) and AMD (hall 2 stand 2M61) at Mobile World Congress 2023 in Barcelona (February 27th – March 2nd).

AMD, the AMD Arrow logo, EPYC™, Zynq™ and Ultrascale+™, and combinations thereof, are trademarks of Advanced Micro Devices, Inc. Other names are for informational purposes only and may be trademarks of their respective owners.

About Mavenir:

Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers and Enterprises in over 120 countries, which serve more than 50% of the world's subscribers. www.mavenir.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

PR Contact:
PR@mavenir.com

Maryvonne Tubb (US)
Emmanuela Spiteri (EMEA)

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Samsung Bioepis Begins Commercialization of BYOOVIZ ® , Biosimilar to Lucentis (Ranibizumab), in Europe2.1.2026 09:00:00 EET | Press release

Samsung Bioepis Co., Ltd. today announced that the company has begun direct commercialization of BYOOVIZ®, a biosimilar to Lucentis1 (ranibizumab), in Europe. Samsung Bioepis has been working to ensure seamless transfer of commercial rights from Biogen back to Samsung Bioepis, and BYOOVIZ will now be available as a Samsung Bioepis brand across multiple European countries. “This is a significant milestone for Samsung Bioepis as the company continues to strengthen its presence in Europe by expanding its portfolio of directly commercialized products. Leveraging the past three years of experience with EPYSQLI (eculizumab) and the newly launched OBODENCE (denosumab) and XBRYK (denosumab) in Europe, we will continue on our journey to become a fully integrated biopharmaceutical company with end-to-end capabilities from development to commercialization,” said Antonio Rito, Vice President and Head of Europe, at Samsung Bioepis. “We will work closely with payers and healthcare professionals to e

Cessna Citation Ascend Enters Into Service, Redefining Performance and Cabin Experience in the Midsize Business Jet Market31.12.2025 16:00:00 EET | Press release

The Cessna Citation Ascend achieved a major milestone as the first retail customer took delivery of the midsize business jet on Tuesday, December 30, marking the aircraft’s entry into service. Announced in 2023 the aircraft boasts an entirely new cockpit, improved performance and a luxurious flat floor cabin. The Citation Ascend received type certification from the Federal Aviation Administration (FAA) in November 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251231586042/en/ Cessna Citation Ascend enters into service, redefining performance and cabin experience in the midsize business jet market. (Photo credit: Textron Aviation) The Cessna Citation Ascend is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company. “The first Citation Ascend delivery underscores Textron Aviation’s commitment to redefining the midsize segment with an aircraft that blends innovation, efficiency and unmatch

Aster Guardians Global Nursing Award 2026 Worth $250,000 Extends Deadline Till 11 th January 202631.12.2025 15:08:00 EET | Press release

The Aster Guardians Global Nursing Award 2026, an initiative from Aster DM Healthcare – a leading integrated healthcare provider, has announced the extension of its deadline to January 11, 2026. The awards have already received over 134,000 registrations from 214 countries, highlighting its growing global reach and recognition among nurses worldwide. Nurses from around the world can submit their nominations through the dedicated platform at www.asterguardians.com. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251231986766/en/ Aster Guardians Global Nursing Award worth USD 250,000 (Photo: AETOSWire) This year, the prestigious award will be hosted in New Delhi, India, celebrating nursing excellence on a truly global stage. The fourth edition of the awards were held in Dubai, UAE where Nurse Naomi Oyoe Ohene Oti was honoured as the winner for her transformative work in cancer care and education that has shaped oncology nursing

Tecnotree Included as a Representative Provider in Gartner ® Innovation Insight: AI SOC Agents Accelerate CSP SecOps Transformation31.12.2025 12:59:00 EET | Press release

Tecnotree, a global digital platform and services provider for communications service providers (CSPs), today announced that it has been referenced as a Representative Provider alongside Google, Anthropic, Dropzone AI, DRUID, Palo Alto Networks, and Pegasystems in the Gartner® Innovation Insight: “AI SOC Agents Accelerate CSP SecOps Transformation,” published in December 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251231210303/en/ Tecnotree Included as a Representative Provider in Gartner® Innovation Insight: AI SOC Agents Accelerate CSP SecOps Transformation The Gartner Innovation Insight examines the emerging role of AI-driven Security Operations Centre (SOC) agents in CSP environments, outlining how these agents are used to automate and augment security operations across signalling, core networks, RAN, Open RAN, and roaming domains. The research discusses use cases such as alert triage, investigation support, thr

UAE’s Medcare Treats First International SMA Patient With Revolutionary Intrathecal Gene Therapy30.12.2025 16:15:00 EET | Press release

Medcare Women & Children Hospital has successfully administered a pioneering intrathecal gene therapy for Spinal Muscular Atrophy (SMA) to Hulus, a three-year-old patient from Turkey. This milestone positions Medcare among the first private healthcare providers worldwide to offer this innovative treatment to an older international patient, overcoming previous age and weight limitations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251230695275/en/ World's first international patient, who received intrathecal gene therapy at Medcare Royal Hospital in Dubai, UAE, along with parents, and the hospital team. (Photo: AETOSWire) SMA is a rare neuromuscular disorder that progressively weakens muscles responsible for movement and breathing. This newly licensed one-time therapy addresses the root genetic cause by delivering a functional SMN1 gene. For Hulus, whose daily routine earlier depended on intensive physiotherapy and hydroth

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye